Day: May 28, 2024

FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) —  Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in June: Jefferies Global Healthcare Conference in New York, NYDate: Wednesday, June 5, 2024Live Webcast: 12:30 p.m. ETManagement to participate in one-on-one meetings throughout the conference Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FLDate: Tuesday, June 11, 2024Live Webcast: 2:40 p.m. ETManagement to participate in one-on-one meetings throughout the conference To access the live webcast and archived recordings of each event, visit the News & Events section...

VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. Absci management is scheduled to present on Monday, June 10th at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously...

BETHESDA, Md., May 28, 2024 (GLOBE NEWSWIRE) — iLearningEngines, Inc. (NASDAQ: AILE) (“iLearningEngines” or “ILE”) a leading Applied AI platform for learning and work automation, today announced it expects to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style...

Accomplished executive will lead integrated marketing strategy to accelerate growthCarla DoddsCarla DoddsDELRAY BEACH, Fla., May 28, 2024 (GLOBE NEWSWIRE) — PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”) today announced the appointment of Carla Dodds as Chief Marketing Officer (CMO). She brings extensive experience in leadership roles encompassing marketing, strategy and operations for major global companies including Walmart, MasterCard, Curacao, Omnilife-Chivas Group, and Penske Media Corporation. As CMO, Dodds will be responsible for leading PetMeds’ integrated marketing strategy including brand and content, digital and lifecycle marketing, co-op media, customer acquisition and retention, customer insights and market research, social media and corporate...

BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to atacicept for the treatment of IgAN. The designation reflects the FDA’s determination that, based on an assessment of data from the Phase 2b ORIGIN clinical trial of atacicept for IgAN, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. “We are pleased that the FDA has determined that the accumulated clinical data of atacicept in IgAN may demonstrate substantial improvement on kidney function...

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) — AZINCOURT ENERGY CORP. (“Azincourt” or the “Company”) (TSX.V: AAZ, OTCQB: AZURF), is pleased to announce that it has completed the winter 2024 diamond drill program at the East Preston uranium project in the Athabasca Basin, Saskatchewan, Canada. The 2024 drill program consisted of 1,086 meters of drilling in four diamond drill holes. Drilling commenced on March 29th and was complete on April 19th. Logging of drill core, sampling, and demobilization of all drill equipment, helicopter, and crews was complete by the end of April. The priority for the 2024 drill program was to follow up on the clay alteration zone and elevated uranium that was identified in the winter of 2023 with a focus on the area of transition between the K and H Zones (Figure 2). Winter 2024 Program The...

ABM will deliver holistic “one team” approach to create an enhanced learning environment that is clean, healthy and efficientNEW YORK, May 28, 2024 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility services, infrastructure solutions, and parking management today announced a 10-year partnership with Utica University to help transform its campus-wide facilities management operations and create engaging and sustainable spaces for students, faculty and staff. As one of the largest providers of higher education facility solutions in the United States, ABM will bring its industry-leading expertise to the Utica, New York, campus through its ABM Performance Solutions™ model, providing a holistic “one team” approach for all facilities services performed across the campus. “We’re excited to begin this decade-long...

– Financing includes participation from new and existing investors –  – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $110.0 million, before deducting placement agent fees and other expenses. The private placement included participation from both new and existing investors...